Small Molecules

04 Mar 2020 Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
04 Mar 2020 Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
04 Mar 2020 Janssen Submits European Marketing Authorisation Application for Ponesimod for Treatment of Adults with Relapsing Multiple Sclerosis
04 Mar 2020 FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet (pirfenidone) in Unclassifiable Interstitial Lung Disease
04 Mar 2020 PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphedema Candidate LYT-100
03 Mar 2020 Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19
03 Mar 2020 Zydus receives Phase I clinical trial permission for ZYBK2 from DCGI
02 Mar 2020 Shionogi Receives Positive CHMP Opinion for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adult Patients With Limited Treatment Options
02 Mar 2020 Takeda Receives Positive CHMP Opinion for ALUNBRIG (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
02 Mar 2020 Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
29 Feb 2020 Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
29 Feb 2020 FDA Grants Breakthrough Therapy Designation for Debiopharm's Novel Chemo-Radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer
29 Feb 2020 AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
29 Feb 2020 Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
27 Feb 2020 Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)
27 Feb 2020 Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
27 Feb 2020 Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug
27 Feb 2020 Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
27 Feb 2020 Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study
27 Feb 2020 Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
27 Feb 2020 European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
26 Feb 2020 Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
26 Feb 2020 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
26 Feb 2020 Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF After Planned Interim Analysis
26 Feb 2020 iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kδ Inhibitor, IOA-244 for Solid Tumours

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top